What Gliclamet treats: main uses and benefits

Gliclamet is a combination oral medication used for the management of type 2 diabetes mellitus. It contains two active pharmacological agents: glibenclamide (a sulfonylurea) and metformin (a biguanide). These two components work through different mechanisms to help control blood glucose levels in adults when diet, exercise, and single-agent therapy do not provide adequate glycemic control.

Primary Indications

The medication is primarily indicated for:

• Type 2 Diabetes Mellitus: Management of high blood sugar in patients whose condition cannot be managed by lifestyle changes alone.
• Combination Therapy: Use in patients who are already stabilized on separate doses of metformin and glibenclamide, or for those whose blood sugar remains high despite treatment with either metformin or a sulfonylurea alone.

Mechanism of Action and Benefits

By combining two different classes of antidiabetic drugs, Gliclamet addresses several physiological aspects of diabetes:

• Stimulation of Insulin Secretion: The glibenclamide component encourages the pancreas to produce and release more natural insulin.
• Reduction of Glucose Production: The metformin component works primarily by decreasing the amount of glucose produced by the liver.
• Improved Insulin Sensitivity: Metformin also helps the body's peripheral tissues, such as muscle, use existing insulin more effectively.
• Reduced Intestinal Absorption: Metformin can slow the absorption of glucose from the digestive tract into the bloodstream.

Therapeutic Goals

The primary benefit of Gliclamet is the achievement of better glycemic control than what might be reached with single-drug therapy. Consistent control of blood sugar levels is a fundamental aspect of diabetes management, aimed at reducing the risk of long-term complications associated with chronic hyperglycemia. This combination approach allows for the use of lower doses of each individual component, which can sometimes improve the overall tolerability of the treatment regimen.

Regulatory References

1. Australian TGA Public Assessment Report for Gliclazide

Who can and cannot use Gliclamet?

This medication is officially designated for use in adults (18 years and older) with Type 2 Diabetes Mellitus when control is insufficient with diet, exercise, or monotherapy. Regulatory bodies have established strict eligibility criteria based on patient health status and organ function.

Condition/Physiological State	Regulatory Status
Severe Renal Impairment	Contraindicated (e.g., eGFR < 30 mL/min/1.73m²).
Severe Hepatic Impairment	Contraindicated.
Type 1 Diabetes, Diabetic Ketoacidosis	Contraindicated.
Pregnancy and Breastfeeding	Not Recommended/Contraindicated.
Children and Adolescents (Under 18)	Not Recommended (Safety and efficacy not established).

The medicine is also contraindicated in patients with conditions causing tissue hypoxia (e.g., heart failure, respiratory failure, recent myocardial infarction), acute alcohol intoxication, or those with a known hypersensitivity to the drug components or related drug classes (sulfonylureas, sulfonamides). Use is restricted in patients with moderate renal impairment or those undergoing iodinated contrast imaging procedures.

Gliclamet (gliclazide and metformin) can interact with a wide range of other medicines, potentially altering blood sugar control and increasing the risk of adverse effects like hypoglycemia (low blood sugar) or lactic acidosis (a rare but serious buildup of lactic acid).

Medicines that can Increase the Risk of Hypoglycemia

Certain medications can increase the blood-sugar-lowering effect of Gliclamet, necessitating careful monitoring and possible dose adjustment by your doctor. These include:

• Other Antidiabetic Agents: Such as insulin or other sulfonylureas.
• Select Anticoagulants: Like warfarin.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Including high-dose aspirin or ibuprofen.
• ACE Inhibitors: Medications like ramipril or lisinopril, often used for high blood pressure.
• Certain Antifungals or Antibiotics: Such as fluconazole or clarithromycin.
• MAO Inhibitors and beta-blockers.

Medicines that can Decrease Blood Sugar Control

Other medicines can increase blood glucose levels, reducing the effectiveness of Gliclamet. These may require an increase in your Gliclamet dose:

• Corticosteroids: Including prednisone.
• Diuretics: Specifically thiazides (like hydrochlorothiazide) and loop diuretics (like furosemide).
• Oral Contraceptives and other hormone preparations.
• Thyroid hormones and sympathomimetics (e.g., certain decongestants).

Other Significant Interactions

• Iodinated Contrast Media: Gliclamet should be temporarily stopped before and after procedures involving iodinated contrast agents (used in certain X-rays and scans) to prevent the risk of lactic acidosis, especially in patients with impaired kidney function.
• Alcohol: Consumption of alcohol can significantly increase the risk of severe hypoglycemia and lactic acidosis, and should be avoided or severely limited while taking Gliclamet.

Always inform your healthcare provider of all prescription, over-the-counter, herbal medicines, and supplements you are taking.

Triggering Insulin Release from the Pancreas

This mechanistic domain covers how the Gliclazide component works by specifically targeting the Sulfonylurea Receptor 1 ( SUR1) on pancreatic beta-cells. By inhibiting the ATP-sensitive potassium channel ( K ATP), the cell depolarizes, triggering a calcium influx that directly leads to the release of insulin, which contributes to the resulting decrease in plasma glucose concentration.

---

Reducing Glucose Output by the Liver

This domain focuses on the action of the Metformin component within the liver, where it modulates the cellular energy balance. Through the inhibition of mitochondrial Complex I and activation of the AMPK pathway, the drug suppresses the process of gluconeogenesis, resulting in a critical reduction in the liver's production and release of glucose into the bloodstream.

---

Combining Mechanisms for Comprehensive Metabolic Control

This cluster explains the synergy of the two components, which modulate distinct regulatory points in glucose metabolism. By simultaneously stimulating insulin secretion and reducing hepatic glucose output while increasing glucose uptake by peripheral tissues, the drug achieves a multi-target action that results in modulation of multiple pathways involved in glucose homeostasis.

How to Use Gliclamet: Official Administration Guidelines

Gliclamet is an oral fixed-dose combination (FDC) tablet for the long-term management of Type 2 Diabetes Mellitus. Its proper use is defined by specific administration principles. Treatment is individualized and adjusted based on the patient’s metabolic response.

---

Administration Scope

Field	Official Instruction
Route of administration	Oral administration. The tablet must be swallowed whole with water.
Dosing schedule	The regimen is individualized. Typical maintenance ranges from 1 to 2 tablets once or twice daily. The maximum dose is restricted to 4 tablets per day (of the 80 mg/500 mg strength).
Timing in relation to meals	The tablet must be taken with meals to align with proper administration guidance, particularly the Metformin component.
Age-group administration rules	The safety and efficacy in children and adolescents have not been established. For older adults, regular renal function monitoring is advised.
Missed-dose rules	If a dose is missed, a patient should not take a double dose to compensate. The subsequent dose should be taken at the usual scheduled time.
Special procedural conditions	The medication must be discontinued 48 hours before elective surgery requiring specific types of anesthesia and can only be resumed 48 hours afterward if normal renal function is confirmed.

---

Resulting Procedural Structure

The required sequence for Gliclamet's administration is governed by the need to integrate two distinct drug components. The dose is typically divided into two administrations daily when a higher dose is necessary. Furthermore, due to constraints related to the Metformin component, the use is prohibited in patients with severe renal or hepatic impairment, and careful dose reduction is mandatory for patients with moderate renal function reduction (GFR 30 to 59 mL/min). This structure defines the standardized approach to using the medicine.

Recent Clinical Evidence Overview

---

Mechanism of Action Investigated

Research has investigated Gliclamet's (a combination drug containing gliclazide and metformin) components. Gliclazide, as a sulfonylurea, is studied for its ability to stimulate the release of insulin from the pancreas, a process thought to be mediated by its binding to specific receptors on pancreatic beta-cells. Metformin is studied for its effect on reducing glucose production by the liver and improving the body's response to insulin.

Efficacy in Glycemic Control

Clinical trials have evaluated the combination therapy in adults with Type 2 Diabetes Mellitus (T2DM). Studies reported reductions in key markers of long-term blood glucose control, including Hemoglobin A1c (HbA1c) and Fasting Plasma Glucose (FPG) levels, over the duration of the trials. For example, one 12-week study focusing on the combination alongside insulin noted an average HbA1c reduction from approximately 8.9% to 7.8% in one participant group, suggesting an improvement in overall glycemic control during the study period.

Safety and Tolerability

Research trials have monitored participants for adverse events. As with other drugs in the sulfonylurea class, studies indicated a risk of hypoglycemia (low blood sugar), although some data suggests that the incidence may be lower compared to certain other sulfonylurea agents. The most commonly reported adverse events in studies involving the combination included gastrointestinal discomfort, which is often associated with the metformin component.

Specific safety evaluations focused on different patient populations. For instance, data indicates that individuals with severe kidney impairment were often excluded from or showed adverse reactions in the studies, highlighting a population that requires careful consideration.

Common questions about Gliclamet (FAQ)

Q: How is Gliclamet different from taking metformin and gliclazide as separate tablets?

A: Gliclamet is a fixed-dose combination (FDC) tablet containing both active ingredients in a single dose. Regulatory documents note that the FDC approach is often cited as having the potential to support adherence to therapy. This method combines the two different pharmacological actions needed to manage blood sugar into one medicine.

Q: What are the most common side effects listed for Gliclamet?

A: Official product labeling classifies side effects based on how frequently they are reported. Very common effects, as categorized in official documentation, are generally gastrointestinal disorders, such as nausea, diarrhea, vomiting, and abdominal pain. Common effects include low blood sugar (hypoglycemia), headache, dizziness, and a metallic taste disturbance.

Q: Is it true that Gliclamet may cause an increased risk of low blood sugar (hypoglycemia)?

A: Yes, official product documentation notes that hypoglycemia, or low blood sugar, is a common adverse reaction. This risk is typically associated with the Gliclazide component, which works by stimulating the release of insulin. Information about the signs of low blood sugar is typically provided in patient material.

Q: Can Gliclamet affect the body's Vitamin B12 levels over time?

A: Official regulatory advisories confirm that a Vitamin B12 deficiency is a documented risk associated with the long-term use of the medicine, specifically due to the Metformin component. Official guidance suggests that monitoring of B12 levels may be considered for patients presenting with risk factors.

Q: Can taking Gliclamet affect the effectiveness of oral contraceptives or hormonal birth control?

A: Official regulatory information states that oral contraceptives and other hormone preparations may increase blood glucose levels, potentially reducing the effectiveness of Gliclamet in controlling blood sugar. Official sources do not describe Gliclamet affecting the efficacy of the contraceptive itself.

Q: What categories of medicines may increase the risk of low blood sugar when taken with Gliclamet?

A: Medicines that may increase the blood-sugar-lowering effect include other antidiabetic agents, non-steroidal anti-inflammatory drugs (NSAIDs), and certain antibiotics. Other categories include ACE inhibitors, MAO inhibitors, select anticoagulants, and beta-blockers.

Q: Is Gliclamet intended for long-term management of Type 2 diabetes?

A: Yes, according to official regulatory documents, Gliclamet is indicated and designated for the long-term management of Type 2 Diabetes Mellitus. The treatment plan is generally individualized and managed over time.

Q: What kind of monitoring blood tests are generally recommended for patients taking Gliclamet long-term?

A: Regulatory documents frequently mention the need for monitoring key markers of long-term blood glucose control, such as Hemoglobin A1c (HbA1c) and Fasting Plasma Glucose (FPG). Furthermore, monitoring of renal (kidney) function and consideration for Vitamin B12 levels is also generally advised.

Q: What happens if a patient experiences frequent or severe vomiting and diarrhea while taking Gliclamet?

A: Frequent or severe vomiting and diarrhea can cause dehydration, which raises the risk of a rare but serious complication called lactic acidosis. If these symptoms occur, regulatory documents advise that immediate medical evaluation is necessary.

Q: How long does it typically take for Gliclamet to begin affecting blood sugar levels?

A: The initial blood sugar-lowering effect is observable relatively soon after the medicine is absorbed, as the Gliclazide component typically reaches peak blood levels within a few hours. Long-term blood glucose control is assessed over a longer period, with overall effectiveness commonly measured by markers like HbA1c after several weeks or months of continuous use.

Q: Does Gliclamet work only by increasing insulin production?

A: No, official product information states that the medicine has a dual action. The Gliclazide component stimulates insulin secretion from the pancreas, but the Metformin component works primarily to reduce the liver’s production of glucose.

Q: Is a metallic taste in the mouth commonly reported when using this drug?

A: Yes, a metallic taste disturbance is officially listed in regulatory documents as a common side effect of the medicine.

Q: What information exists about Gliclamet and weight change (gain or loss)?

A: Official product labeling cites weight gain as a potential effect, which is typically associated with the Gliclazide component (a sulfonylurea). The combination is not described in regulatory documents as promoting weight loss.

Q: What are the signs of a severe allergic reaction or serious skin reaction to Gliclamet?

A: Regulatory documents list potential serious adverse reactions, which can include rash, redness (erythema), and hives (urticaria). Signs of a severe allergic reaction, such as facial swelling, blistering of the skin, or difficulty breathing, are noted as requiring immediate medical evaluation.

Q: Does Gliclamet interact with other common non-prescription medicines or supplements?

A: Official documentation cautions that certain non-prescription items and herbal remedies may affect blood sugar control. For example, the herbal preparation St John's wort is specifically mentioned as a product that should be avoided as it may decrease the drug's effectiveness.

Q: Are there specific herbal supplements that are known to interact with Gliclamet?

A: Yes, the herbal preparation St John's wort (Hypericum perforatum) is specifically noted in regulatory documentation. It is cited as potentially decreasing the exposure to the Gliclazide component, which may lead to a loss of blood sugar control.

Q: Is Gliclamet known to cause dizziness or affect a person's ability to concentrate?

A: Dizziness is documented as a common side effect. Difficulty concentrating is also listed as a potential symptom of low blood sugar (hypoglycemia). Official guidance includes caution regarding activities such as driving or operating machinery until the individual's response to the medicine is known.

Q: Is it possible for Gliclamet to affect a patient's eyesight or cause blurred vision?

A: Regulatory documents do not list blurred vision as a direct side effect of the medicine. However, blurred vision is noted as a potential symptom that can occur in association with changes in blood sugar, particularly during episodes of severe low blood sugar (hypoglycemia).

Q: What is the guidance on using Gliclamet during pregnancy?

A: Official guidance states that Gliclamet is generally not recommended during pregnancy. This is due to limited safety data and a potential risk of harm to the newborn, such as low blood sugar. Insulin is the preferred medication for diabetes treatment during pregnancy.

Q: What is the guidance on using Gliclamet while breastfeeding?

A: The product is generally contraindicated (not recommended) during breastfeeding. This is due to the risk of neonatal hypoglycemia (low blood sugar in the newborn), as it is unknown if the components are excreted in human milk.

Q: Is Gliclamet ever used in the pediatric population (children and adolescents)?

A: Regulatory documents state that Gliclamet is not recommended for use in children and adolescents (under 18). This status is maintained because the safety and effectiveness of the medicine in this population have not been established through research.

Q: What is the relationship between Gliclamet and the body's natural insulin secretion?

A: The Gliclazide component acts by stimulating the beta cells in the pancreas. This action results in an increase in the body's natural secretion of insulin, affecting both basal and meal-stimulated insulin release.

Q: Does Gliclamet have different strengths or forms available?

A: Gliclamet is available as a fixed-dose combination tablet containing specific amounts of Gliclazide and Metformin. Regulatory sources document that these tablets are generally manufactured in one or more specific strength combinations to suit individualized treatment needs.

Q: What kind of skin reactions are sometimes reported with Gliclamet?

A: Official product information lists several reported skin reactions. These include rash, pruritus (itching), urticaria (hives), erythema (redness), and flushing.

How to Store and Dispose of Gliclamet?

To maintain the quality and integrity of Gliclamet (Gliclazide/Metformin), follow the official storage and disposal requirements.

---

Storage Conditions

Temperature and Protection: The medicine must be stored at Controlled Room Temperature, generally between 20 C and 25 C (68 F and 77 F). The product must be protected from light and stored in a dry place. It is mandatory not to refrigerate or freeze the tablets.

Container and Safety: Keep Gliclamet in its original, tightly closed, light-resistant container. As a safety precaution, the medicine must be stored out of the sight and reach of children.

---

Disposal Requirements

Do not dispose of Gliclamet via wastewater (e.g., toilet or sink). Unused or expired medication should be disposed of in accordance with local regulatory requirements. Using a medicine take-back program is the preferred method for proper disposal.